• Molecular NameDicycloverine
  • SynonymNA
  • Weight309.494
  • Drugbank_IDDB00804
  • ACS_NO77-19-0
  • Show 3D model
  • LogP (experiment)5.476
  • LogP (predicted, AB/LogP v2.0)4.89
  • pka9.0
  • LogD (pH=7, predicted)3.11
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)-1.89
  • LogSw (predicted, AB/LogsW2.0)0.07
  • Sw (mg/ml) (predicted, ACD/Labs)0.04
  • No.of HBond Donors0
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds8
  • TPSA29.54
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn anticholinergic that blocks muscarinic receptors.
  • Absorption_valueN/A
  • Absorption (description)Rapidly absorbed after oral administration.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding99.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half life1.8 h
  • ExcretionAbout 80% of a dose is excreted in the urine and 10% is eliminated in the faeces.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most important side effects are constipation, decreased sweating, dryness of mouth, nose, throat, or skin.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A